Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Go back to Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder| (NASDAQ: VTGN) | Delayed: 0.24 +0.01 (4.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.23 | 52 Week High | $4.60 | |||
| Open | $0.23 | 52 Week Low | $2.81 | |||
| Day High | $0.25 | P/E | N/A | |||
| Day Low | $0.23 | EPS | $0.00 | |||
| Volume | 718,462 | |||||
